GC Biopharma introduces candidates for treating blood coagulation disease

South Korea's GC Biopharma Corp. announced on Tuesday that it had entered into an agreement to transfer assets with Catalyst Biosciences, a US-based drug development firm, in order to introduce drug candidates for a rare blood coagulation disease.

The Korean drug maker will acquire a total of three candidates, including MarzAA, which is currently in the global phase 3 clinical trials. GC Biopharma claims that MarzAA has demonstrated effectiveness and safety in previous clinical trials and is being developed as a subcutaneous injection formulation.

The company intends to continue conducting clinical trials on the candidate substances with the aim of launching a new drug. Previously, GC Biopharma successfully developed Green Mono and Greengene F for hemophilia, one of the blood clotting disorders.

"We will expand our efforts globally to improve the treatment options for patients suffering from various rare diseases, including rare blood clotting disorders," said Huh Eun-chul, CEO of GC Biopharma.

Write to Jae-Young Han at jyhan@hankyung.com